Dr. Mark Kotter
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy.
His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna.
Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
RELATED INSIGHTS
Meatable: Cell-based meat startup secures $47m Series A for scalable technology
The Dutch startup offers a pioneering technology for quickly scaling cell-based meat production while eliminating the need for animal-derived growth media
Meatable joins Royal DSM to create growth media specific for cell-based meat tech
The R&D between the biotech startup and fellow Dutch nutrition conglomerate could help scale and drive the commercial viability of lab-grown meat
RECOMMENDED
